<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02926989</url>
  </required_header>
  <id_info>
    <org_study_id>EETTMK 48/2016</org_study_id>
    <nct_id>NCT02926989</nct_id>
  </id_info>
  <brief_title>Intravenous Fluids in Hospitalised Children</brief_title>
  <official_title>Isotonic Versus Hypotonic Intravenous Fluids in Hospitalised Children - a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the trial is to evaluate the risk of hypokalemia following
      administration of a isotonic solution compared to a hypotonic solution in acutely ill
      hospitalised children, who need intravenous fluid therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the trial is to evaluate the risk of hypokalemia (low plasma potassium
      concentration) following administration of a Plasmalyte Glucos 50 mg/mL solution compared to
      a 0.45% saline in 5% dextrose solution in acutely ill hospitalised children, who need
      intravenous fluid therapy. The secondary objective of the trial is to evaluate the risk of
      hyponatremia (low plasma sodium concentration) and the risk of hypernatremia (high plasma
      sodium concentration) following administration of isotonic solution compared to hypotonic
      solution.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of hypokalemia</measure>
    <time_frame>Plasma sodium and potassium concentrations are assessed daily (at 7 am) during the intravenous fluid therapy from randomization up to seven days.</time_frame>
    <description>Plasma potassium concentration of lower than 3.5 mmol/L.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of hyponatremia</measure>
    <time_frame>Plasma sodium and potassium concentrations are assessed daily (at 7 am) during the intravenous fluid therapy from randomization up to seven days.</time_frame>
    <description>Plasma sodium concentration of lower than 132 mmol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypernatremia</measure>
    <time_frame>Plasma sodium and potassium concentrations are assessed daily (at 7 am) during the intravenous fluid therapy from randomization up to seven days.</time_frame>
    <description>Plasma sodium concentration of higher than 148 mmol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>Body weight is measured daily (at 7 am) during the intravenous fluid therapy from randomization up to seven days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of intravenous fluid regimen</measure>
    <time_frame>From randomization up to seven days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amounts of extra sodium and potassium added to solutions</measure>
    <time_frame>From randomization up to seven days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of intravenous fluid therapy</measure>
    <time_frame>From randomization up to seven days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to ICU</measure>
    <time_frame>From randomization up to seven days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge</measure>
    <time_frame>From randomization up to seven days.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">610</enrollment>
  <condition>Hypokalemia</condition>
  <condition>Hyponatremia</condition>
  <condition>Hypernatremia</condition>
  <condition>Dehydration</condition>
  <arm_group>
    <arm_group_label>Isotonic solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasmalyte Glucos 50 mg/mL; total daily fluid requirements are estimated using the Holiday-Segar method plus possible dehydration (according to child's weight loss during acute illness); intravenous fluids are administered using delivery pumps programmed for an hourly infusion rate (mL/hour); intravenous fluids are administered as long as needed during hospitalization, but no longer than seven days after admission.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypotonic solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.45% saline in 5% dextrose; total daily fluid requirements are estimated using the Holiday-Segar method plus possible dehydration (according to child's weight loss during acute illness); intravenous fluids are administered using delivery pumps programmed for an hourly infusion rate (mL/hour); intravenous fluids are administered as long as needed during hospitalization, but no longer than seven days after admission.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plasmalyte Glucos 50 mg/mL</intervention_name>
    <description>Solution contains potassium chloride 5 mmol/L and sodium chloride 140 mmol/L.</description>
    <arm_group_label>Isotonic solution</arm_group_label>
    <other_name>ATC-code: B05BB02</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.45% saline in 5% dextrose</intervention_name>
    <description>Solution contains potassium chloride 20 mmol/L and sodium chloride 80 mmol/L.</description>
    <arm_group_label>Hypotonic solution</arm_group_label>
    <other_name>0.45% NaCl in 5% dextrose.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acutely ill hospitalised children

          -  Need for intravenous fluid therapy

        Exclusion Criteria:

          -  An initial plasma sodium concentration of lower than 130 mmol/L

          -  An initial plasma sodium concentration of higher than 150 mmol/L

          -  An initial plasma potassium concentration of lower than 3.0 mmol/L

          -  Need for 10% glucose solution

          -  Diabetes

          -  Diabetes insipidus

          -  Diabetic ketoacidosis

          -  Renal disease that needs dialysis

          -  Protocol-determined chemotherapy hydration

          -  Severe liver disease

          -  Inborn errors of metabolism that need protocol-determined fluid therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terhi Tapiainen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Minna Honkila, MD</last_name>
    <phone>+35883155863</phone>
    <email>minna.honkila@ppshp.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Terhi Tapiainen, MD PhD</last_name>
    <phone>+35883155185</phone>
    <email>terhi.tapiainen@oulu.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minna Honkila, MD</last_name>
      <phone>+35883155863</phone>
      <email>minna.honkila@ppshp.fi</email>
    </contact>
    <contact_backup>
      <last_name>Terhi Tapiainen, MD PhD</last_name>
      <phone>+35883155185</phone>
      <email>terhi.tapiainen@oulu.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Saara Lehtiranta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Merja Kallio, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Niko Paalanne, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Outi Peltoniemi, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tytti Pokka, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hannele Pruikkonen, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marjo Renko, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Minna Honkila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Terhi Tapiainen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2016</study_first_submitted>
  <study_first_submitted_qc>October 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oulu</investigator_affiliation>
    <investigator_full_name>Terhi Tapiainen</investigator_full_name>
    <investigator_title>Adjunct professor</investigator_title>
  </responsible_party>
  <keyword>Isotonic</keyword>
  <keyword>Hypotonic</keyword>
  <keyword>Intravenous fluids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyponatremia</mesh_term>
    <mesh_term>Dehydration</mesh_term>
    <mesh_term>Hypernatremia</mesh_term>
    <mesh_term>Hypokalemia</mesh_term>
    <mesh_term>Potassium Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma-lyte 148</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

